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Those strains that failed to develop tolerance belongd to a variety of phage patterns comprising reactions in Groups I and III, but no consistent feature could be identified. The strain that became tolerant without showing any subsequent change belonged to phage type 187 (at 1,000 x RTD). The phage patterns of the 3 parental strains that later developed resistance and other changes were 42D, 29/77 (at 1,OOOxRTD) and 29/52/52A/80 (at 1,000 x RTD) respectively.
These three phage patterns are not infrequently found in clinically isolated mercury-resist strains of staphylococci. This suggests that ability to develop tolerance to high levels of mcuric chloride may be possessed only by staphylococci susceptible to certain bacteriophages, and that this ability (accompanied as it generally is by multiple resistance to antibiotics) is genetically determined. The strain lysed by phage 187 did not show any change in the experiments other than developmnt of tolerance to mercuric chloride, and staphylococci of phage type 187 that are isolated clinically are usually mercurysensitive and are sensitive to antibiotics.
The conditions of the experiment were artificial in that the duration and degree of exposure to mercuric chloride were far in excess of anything that would be encountered naturally and the strains were assailed with mercuric ions only, whereas under hospital conditions there would be additional exposure to antibiotics and other agents. In addition, the extent of injury was such that some of the derivatives could no longer be identified as Staphylococcus aureus per se.
However, the evidence suggests that, in some cases at least, antibiotic resistance can emerge as a result of biochemical injury and it is possible that agents other than mercuric chloride can inflict such injury. 
Cbemotheapy of Vhis Infecdons [Abstract]
Until quite recently the control of virus diseases has been entirely dependent upon vaccinition. Notable successes have been achieved, but it is becoming clear that the immunological approach does not provide the complete answer to the problem, and it is therefore fotunate tha specific chemotherapy is becoming available, for both prevention and treatment of virus diseases.
In general, virus diseases cannot be treated with vaccines or antisera, but there is no theoretical obstacle to the treatment of viru dis with drugs, since the situation does not differ from the treatment of infectious diseases caused by other kinds of agents. If a virus disease can be ,trted, it should be possible to prevent it by administering the specific drug during the incbation period. Treatment may not be possible for practical reasons, but such diseases could still be controlled by prophylaxis. There is, however, a large class of virus infections in which cbemotherapy may not be possible. These include upper respiratory infections and the febrile ilnesses prevalent in the tropics; although specific treatment may be available, the diaosis cannot be made with sufficient precisionon clinical grounds, and diseases of this type will only Section ofExperimental Medicine & Therapeutics with Section of Pathology. 545 become amenable to treatment if an antiviral drug with a very wide spectrum of activity is discovered.
Treatment may not be possible if the onset is acute and virus multiplication has nearly reached its peak, but some virus diseases have features which make them very amenable to treatment. The course may be fairly protracted, as in measles, chickenpox and cutaneous herpes. Skin diseases such as warts, molluscum contagiosum and vaccinia gangrenosa last for months. Virus infections of the eye draw attention to themselves from the outset on account of the severity of the symptoms. Other virus diseases have a prodromal phase or a biphasic course, so that there is sufficient time to begin treatment if the diagnosis can be made.
There are no antiviral drugs listed as yet in the British Pharmacopoeia or the United States Dispensatory, but there are three in the 25th edition of Martindale's Extra Pharmacopeia, namely methisazone, idoxuridine and amantadine hydrochloride.
Methisazone has a very wide spectrum of antiviral activity, which includes several groups of DNA and RNA viruses, but its use in man is so far confined to smallpox and vaccinia infections. It is indicated for the prophylaxis of smallpox and alastrim, mitigation of primary vaccination, and the treatment of eczema vaccinatum and vaccinia gangrenosa.
In a trial carried out in Madras in 1963 methisazone was given to 2,610 persons who had been in close'contact with smallpox patients. During an observation period of 14 days, chosen so as to cover one incubation period, 18 developed smallpox and 4 died. A comparable untreated' group of 2,710 persons was also kept under observation. Among them 113 developed smallpox and 21 died. The case incidence in this group was 4-17%, compared with 0-69% in the treated group, a reduction of seven-fold.
Chemoprophylaxis obtained with drugs differs from prophylaxis with vaccines. A vaccine confers protection against an infection which is going to be encountered some time in the future, whereas chemoprophylaxis will only eradicate an infection which is developing during the incubation period, but if the contact has escaped infection chemoprophylaxis can clearly do nothing. The protective effect of the drug is only maintained as long as it is present in the body in effective concentration. If further exposure is incurred the prophylactic treatment must be repeated. Eczemla vaccinatum occurs in eczematous patients, usually infants, who have mistakenly been given smallpox vaccine, or who have accidentally been infected with vaccinia virus by contact with vaccinated persons. A generalized eruption of vesicles and pustules appears, which closely resembles smallpox. The mortality may be as high as 30%. The condition responds well to treatment with methisazone. Vaccinia gangrenosa occurs in patients with a defective immune response. The juvenile type occurs in infants with hypogammaglobulinemia, and the adult type in patients with leukeemia and other reticuloses who are vaccinated, usually for travel purposes to pay a farewell visit to relatives overseas. Both types are invariably fatal in the absence of treatment. Recovery has been obtained after massive doses of antivaccinial gamma globulin, and also with methisazone treatment, either alone, combined, or after treatment with gamma globulin has failed. In the juvenile type, patients with a single immunological defect respond well, but neither treatment is successful in the presence of multiple immunological defects. It appears that the presence of functioning leukocytes is necessary if treatment is to be successful. Methisazone has also been reported to be effective in the treatment of varicellar pneumonia. Its main side-effects are nausea, vomiting and intolerance of alcohol.
Idoxuridine is a nucleoside analogue. Its spectrum of activity covers a range of DNA viruses, including vaccinia, herpes, adenovirus and varicella-zoster. Its effectiveness in treating herpetic keratitis in man has been demonstrated in a number of trials, and it is the standard treatment for this condition. It is ineffective if the disease has prQgressed to involve the stroma, and prolonged treatment may lead to the emergence of resistant strains. It is also effective in keratitis due to vaccinia and zoster viruses. Cutaneous herpes has been successfully treated with idoxuridine in the form of a 0 5 % ointment and also as a 5 % solution in dimethylsulphoxide, and attempts have been made to treat herpetic encephalitis with infusions of idoxuridine in saline. Idoxuridine is not really suitable for systemic administration, as it is rapidly metabolized into inactive derivatives. For the treatment of eye infections it should be administered every two hours. Pruritus, cedema and photophobia may occur as side-effects.
Amantadine hydrochloride has a moderate inhibitory effect on the multiplication of types A, Al and A2 influenza virus in laboratory systems. In spite of its relatively low level of antiviral activity it has been subjected to extensive clinical trials and issued for general use. The evidence for activity in man is conflicting. No effect could be detcted in a double4blind trial in volunteers infected intanasally with type A2 influenz virus. The best result was obtained in a prophylactic trial carried out in this country during an epidemic of A2 influnza in 1967-8. Family contacts of influenza patients were given 100 mg of the drug every 12 hours for 10 days, or similar doses of a placebo, by random allocation. Among 48 contacts trea-ted with amantadine hydrochloride there were no cases of influeza during the observation period, whereas there were 10 cases among 69 contacts given the placebo.
The case incidences were zero and 14'S % respectively, and the significance of the difference was 001-405. Side-effects are frequent, and inchlde depression, drowsiness and insomnia. The only indication for the drug is the prophylaxis of A2 influenza. Antiviral chemotherapy is thus an established fact, with two drugs of proven efficacy and another undergoing practical evaluation. It is unfortunate that the diseases which are susceptible to antiviral drugs are mainly of secondary importance, but this is an inevitable consequence of the random manner in which discoveries are made. Intensive efforts are being made to find compounds active against respiratory viruses, and when this is achieved antiviral drugs will be within the prescribing range of the general practitioner.
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